Actinium Pharmaceuticals (ATNM) Stock Price Down 11.7%

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was down 11.7% during trading on Monday . The stock traded as low as $0.47 and last traded at $0.48. Approximately 1,319,186 shares changed hands during mid-day trading, an increase of 72% from the average daily volume of 766,801 shares. The stock had previously closed at $0.54.

Several equities research analysts recently commented on ATNM shares. Maxim Group set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 5th. Oppenheimer set a $5.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 26th. Finally, Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research note on Monday, April 1st. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $3.50.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06).

Several hedge funds have recently made changes to their positions in ATNM. Virtu Financial LLC lifted its position in Actinium Pharmaceuticals by 103.1% in the third quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 99,318 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Actinium Pharmaceuticals by 23.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 198,480 shares during the last quarter. Vanguard Group Inc. lifted its position in Actinium Pharmaceuticals by 6.4% in the third quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after buying an additional 154,403 shares during the last quarter. Finally, Vanguard Group Inc lifted its position in Actinium Pharmaceuticals by 6.4% in the third quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after buying an additional 154,403 shares during the last quarter.

WARNING: This news story was published by PressOracle and is the sole property of of PressOracle. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://pressoracle.com/news/2019/04/17/actinium-pharmaceuticals-atnm-stock-price-down-11-7.html.

Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

See Also: Closed-End Mutual Funds

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.